ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) today released policy principles reaffirming the pharmaceutical distribution industry’s commitment to ensuring — in partnership with federal and state governments — the safe and efficient distribution of COVID-19 vaccines once they are approved by the Food and Drug Administration. HDA highlights four priority areas for vaccine distribution:
NEW YORK — The effort to develop a safe and effective vaccine for COVID-19 has been an all-hands-on-deck approach ever since the virus began wreaking havoc across the globe earlier this year. But it seems now, with the presidential election less than two months away — and with President Trump promising a vaccine “very soon”
WASHINGTON — The Department of Health and Human Services (HHS) this month authorized pharmacists to order and administer COVID-19 vaccination, a move welcomed by pharmacy advocates. “This is an extremely important decision by the administration,” said National Association of Chain Drug Stores president and chief executive officer Steve Anderson. “When safe and effective COVID-19 vaccinations
ARLINGTON, Va. — NACDS president and CEO Steven Anderson issued a statement Thursday upon the U.S. Department of Health and Human Services (HHS) issuanceof guidance under the Public Readiness and Emergency Preparedness Act (PREP Act) to expand access to safe and effective COVID-19 vaccines when they are made available. This guidance authorizes state-licensed pharmacists to
WASHINGTON — The U.S. Department of Health and Human Services (HHS) authorized pharmacists and pharmacist interns to order and administer COVID-19 vaccines that have been approved or licensed by the Food and Drug Administration (FDA) to all individuals age 3 or older. Pharmacist interns must do so while acting under the supervision of qualified pharmacist.
CAMBRIDGE, Mass.— Moderna announced that the U.S. government has secured 100 million doses of mRNA-1273 as part of the U.S. government’s goal of securing early access to safe and effective COVID-19 vaccines for the American people. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of mRNA-1273
NEW YORK — Pfizer and BioNTech SE announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Under the agreement, the U.S.
WASHINGTON — The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has established a new clinical trials network that aims to enroll thousands of volunteers in large-scale clinical trials testing a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19. The COVID-19 Prevention Trials
LONDON — GSK has confirmed its intention to manufacture 1 billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted COVID-19 vaccine candidates. GSK believes that its pandemic adjuvant technology could make a significant contribution against COVID-19. As demonstrated in the last flu pandemic, GSK’s pandemic adjuvant can
CAMBRIDGE, U.K. — AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organizations to make the University of Oxford’s vaccine widely accessible around the world in an equitable manner. The company has concluded the first agreements for at least 400 million doses and
NEW YORK — Pfizer and BioNTech SE announced Tuesday that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.
BETHESDA, Md. — The National Institutes of Health (NIH) announced Wednesday a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic. With a $1.5 billion investment from federal stimulus funding, the newly launched Rapid Acceleration of Diagnostics (RADx)